Valuation: SI-BONE, Inc.

Market Cap 737M 647M 602M 552M 1.04B 70.98B 1.05B 7.15B 2.79B 34.9B 2.77B 2.71B 121B P/E 2026 *
-38.2x
P/E 2027 * -45.8x
Enterprise Value 737M 647M 602M 552M 1.04B 70.98B 1.05B 7.15B 2.79B 34.9B 2.77B 2.71B 121B EV / Sales 2026 *
3.18x
EV / Sales 2027 * 2.76x
Free-Float
96.58%
Yield 2026 *
-
Yield 2027 * -
1 day+0.91%
1 week-4.37%
Current month+1.84%
1 month+1.71%
3 months+22.93%
6 months-1.07%
Current year-15.72%
1 week 16.26
Extreme 16.26
17.36
1 month 15.75
Extreme 15.75
18.17
Current year 11.48
Extreme 11.48
21.89
1 year 11.48
Extreme 11.48
21.89
3 years 11.48
Extreme 11.48
26.03
5 years 11.14
Extreme 11.14
30.87
10 years 7.2
Extreme 7.2
37.21
Manager TitleAgeSince
Chief Executive Officer 59 2021-04-19
Director of Finance/CFO 46 2021-04-18
Chief Tech/Sci/R&D Officer 64 2017-01-31
Director TitleAgeSince
Chairman 71 2008-03-17
Director/Board Member 72 2012-12-31
Director/Board Member 56 2008-03-17
Date Insider Type Main position Quantity % Market Cap.
7/2/26 Sell

Chief Financial Officer

-3,317 0.0075%
7/2/26 Sell

General Counsel

-3,134 0.0071%
6/5/26 Sell

Founder

-3,575 0.0081%
Change 5-day change 1-year change 3-year change Capi.($)
+0.91%-4.37%-4.26%-33.65% 730M
+0.26%+0.13%+38.47%+5.31% 12.5B
+0.52%-0.95%+14.98%+20.01% 6.39B
-0.53%-5.32%+42.66%+19.08% 5.5B
+3.06%-0.59% - - 4.59B
-3.39%+1.63%-27.77%+18.23% 4.47B
-2.85%-2.49%-25.95%-24.17% 4.03B
-11.71%+10.87%+40.75%-53.95% 2.32B
-0.34%-4.23%-12.63%+204.03% 1.71B
+0.33%+0.33%+56.28%-2.70% 1.55B
Average -1.37%+0.63%+13.61%+16.91% 4.38B
Weighted average by Cap. -0.81%+0.78%+18.85%+12.21%

Financials

2026 *2027 *
Net sales 232M 203M 189M 174M 326M 22.31B 331M 2.25B 878M 10.97B 870M 851M 37.92B 267M 234M 218M 200M 375M 25.68B 381M 2.59B 1.01B 12.62B 1B 979M 43.65B
Net income -19.59M -17.21M -16M -14.68M -27.59M -1.89B -28.02M -190M -74.24M -928M -73.55M -71.96M -3.21B -16.77M -14.73M -13.7M -12.57M -23.62M -1.62B -23.98M -163M -63.55M -794M -62.96M -61.6M -2.75B
Net Debt - -
Logo SI-BONE, Inc.
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
Employees
376
Date Price Change Volume
26-07-24 US$16.62 +0.91% 381,073
26-07-23 US$16.47 -1.44% 331,108
26-07-22 US$16.71 -1.94% 408,081
26-07-21 US$17.04 -0.47% 436,903
26-07-20 US$17.12 -1.50% 371,810
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
16.62USD
Average target price
24.50USD
Spread / Average Target
+47.41%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SIBN Stock